Pediatr Blood Cancer

• 

  Publication Venue For

  • Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study..  66:e27736. 2019
  • Insights into pediatric rhabdomyosarcoma research: Challenges and goals..  e27869. 2019
  • A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer..  66:e27568. 2019
  • Ethical considerations of using a single minor donor for three bone marrow harvests for three HLA-matched siblings with primary immunodeficiency..  66:e27602. 2019
  • Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma..  66:e27491. 2019
  • Transition to adult care in sickle cell disease: A longitudinal study of clinical characteristics and disease severity..  66:e27463. 2019
  • Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study..  65:e27304. 2018
  • Translation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in Malawi..  65:e27353. 2018
  • Mobile health intervention for youth with sickle cell disease: Impact on adherence, disease knowledge, and quality of life..  65:e27081. 2018
  • Bleeding and thrombotic complications of pediatric liver transplant..  65:e26955. 2018
  • Inconsistency in classifying vascular anomalies: What's in a name?.  65. 2018
  • Comparing oncologic outcomes after minimally invasive and open surgery for pediatric neuroblastoma and Wilms tumor..  65. 2018
  • MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group..  64. 2017
  • Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience..  64. 2017
  • Renal medullary carcinoma: A national analysis of 159 patients..  64. 2017
  • The clinical severity of hemoglobin S/Black (A γδβ)0 -thalassemia..  64. 2017
  • A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group..  64. 2017
  • Development of quality indicators for transition from pediatric to adult care in sickle cell disease: A modified Delphi survey of adult providers..  64. 2017
  • Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents..  64. 2017
  • Hepatocellular adenoma among adult survivors of childhood and young adult cancer..  64. 2017
  • Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program..  64. 2017
  • Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program..  64. 2017
  • Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative..  64. 2017
  • Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia..  63:1856-1859. 2016
  • Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program..  63:1744-1752. 2016
  • Understanding splenectomy for children with hereditary spherocytosis..  63:1700-1701. 2016
  • Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease..  63:1031-1037. 2016
  • Responsiveness of PROMIS® Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery..  63:1038-1045. 2016
  • Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program..  63:443-450. 2016
  • Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program..  63:276-286. 2016
  • Tobacco Use Among Siblings of Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study..  63:326-333. 2016
  • Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience..  62:2216-2222. 2015
  • Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations..  62:1855-1858. 2015
  • Use of patient registries and administrative datasets for the study of pediatric cancer..  62:1495-1500. 2015
  • Value of surgical resection in children with high-risk neuroblastoma..  62:1529-1535. 2015
  • Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study..  62:1190-1194. 2015
  • Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program..  62:1106-1109. 2015
  • Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?.  62:929-930. 2015
  • Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children?.  62:922-923. 2015
  • Humanism and professionalism education for pediatric hematology-oncology fellows: A model for pediatric subspecialty training..  62:335-340. 2015
  • Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673..  62:91-98. 2015
  • Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program..  61:1972-1979. 2014
  • Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program..  61:1486-1489. 2014
  • Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program..  61:1493-1496. 2014
  • Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial..  61:1427-1433. 2014
  • Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study..  61:1440-1444. 2014
  • Patterns of symptoms and functional impairments in children with cancer..  61:1282-1288. 2014
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome..  61:1126-1128. 2014
  • Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers..  61:1074-1079. 2014
  • Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell disease..  61:875-878. 2014
  • Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group..  61:729-736. 2014
  • Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program..  61:245-252. 2014
  • Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease..  61:291-296. 2014
  • Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies..  61:360-362. 2014
  • Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program..  61:158-164. 2014
  • Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children..  60:1967-1974. 2013
  • Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program..  60:1860-1867. 2013
  • Acute toxicity of proton beam radiation for pediatric central nervous system malignancies..  60:1431-1436. 2013
  • Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program..  60:1325-1332. 2013
  • Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia..  60:1358-1364. 2013
  • Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program..  60:E42-E45. 2013
  • The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians..  60:1231-1236. 2013
  • Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program..  60:783-790. 2013
  • Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program..  60:791-798. 2013
  • A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group..  60:543-549. 2013
  • High rates of recurrent biliary tract obstruction in children with sickle cell disease..  60:650-652. 2013
  • Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program..  60:633-641. 2013
  • Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience..  60:694-699. 2013
  • Potential role for statins in sickle cell disease..  60:550-557. 2013
  • Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program..  59:1266-1274. 2012
  • Ambulatory care connections of Medicaid-insured children with sickle cell disease..  59:888-894. 2012
  • Severe fetal and neonatal hemolytic anemia due to a 198 kb deletion removing the complete β-globin gene cluster..  59:941-944. 2012
  • Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program..  59:749-752. 2012
  • Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program..  59:586-588. 2012
  • Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program..  59:518-524. 2012
  • Feasibility of neurobehavioral screening following diagnosis of pediatric cancer..  59:295-300. 2012
  • Health-related quality of life in sickle cell disease: past, present, and future..  59:377-385. 2012
  • Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children..  59:365-371. 2012
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program..  59:329-332. 2012
  • Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program..  59:246-253. 2012
  • Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data..  59:21-26. 2012
  • Evaluation of partial and total splenectomy in children with sickle cell disease using an Internet-based registry..  59:100-104. 2012
  • Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort..  59:126-132. 2012
  • Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program..  59:185-188. 2012
  • Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program..  58:916-923. 2012
  • Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program..  58:729-735. 2012
  • Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling..  58:815-818. 2012
  • A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children..  58:513-518. 2012
  • Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program..  58:566-571. 2012
  • Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program..  58:636-639. 2012
  • Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program..  58:191-199. 2012
  • Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program..  58:200-209. 2012
  • Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia..  58:31-36. 2012
  • Childhood cancer survivorship educational resources in North American pediatric hematology/oncology fellowship training programs: a survey study..  57:1186-1190. 2011
  • Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice..  57:1239-1243. 2011
  • Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study..  57:1210-1216. 2011
  • Initial testing of lenalidomide by the pediatric preclinical testing program..  57:606-611. 2011
  • Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program..  57:443-453. 2011
  • Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program..  57:268-274. 2011
  • ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy..  56:1055-1061. 2011
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group..  56:1041-1045. 2011
  • Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan..  56:818-824. 2011
  • Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program..  56:595-603. 2011
  • Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program..  55:1329-1337. 2010
  • Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program..  55:1126-1133. 2010
  • Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program..  55:668-677. 2010
  • Spontaneous resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis..  55:754-756. 2010
  • Impact of continuous renal replacement therapy on oxygenation in children with acute lung injury after allogeneic hematopoietic stem cell transplantation..  55:540-545. 2010
  • Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program..  55:295-303. 2010
  • Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)..  55:26-34. 2010
  • Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program..  54:921-926. 2010
  • Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group..  54:663-669. 2010
  • Initial testing of topotecan by the pediatric preclinical testing program..  54:707-715. 2010
  • Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group..  54:596-602. 2010
  • Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia..  54:199-205. 2010
  • Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program..  54:307-310. 2010
  • Health related quality of life in sickle cell disease: just scratching the surface..  54:1-2. 2010
  • Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program..  53:1255-1263. 2009
  • Survey of long-term follow-up programs in the United States for survivors of childhood brain tumors..  53:1295-1301. 2009
  • Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection..  53:1120-1123. 2009
  • Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program..  53:594-598. 2009
  • Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program..  53:505-508. 2009
  • Initial testing of aplidin by the pediatric pre-clinical testing program..  53:509-512. 2009
  • A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia..  52:609-615. 2009
  • Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia..  52:531-534. 2009
  • Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome..  52:536-538. 2009
  • Assessment of selection bias in clinic-based populations of childhood cancer survivors: a report from the childhood cancer survivor study..  52:379-386. 2009
  • Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors..  52:169-176. 2009
  • Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma..  51:675-678. 2008
  • Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program..  51:439-441. 2008
  • Abnormalities in glucose tolerance are common in children with fanconi anemia and associated with impaired insulin secretion..  51:256-260. 2008
  • Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program..  51:42-48. 2008
  • Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program..  51:34-41. 2008
  • A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation..  50:1240-1246. 2008
  • Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program..  50:1190-1197. 2008
  • Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program..  50:1181-1189. 2008
  • Initial testing of dasatinib by the pediatric preclinical testing program..  50:1198-1206. 2008
  • Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease..  50:1006-1012. 2008
  • Initial testing of cisplatin by the pediatric preclinical testing program..  50:992-1000. 2008
  • Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia..  50:1072-1075. 2008
  • Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program..  50:799-805. 2008
  • Acute myelogenous leukemia associated with Ollier disease..  50:645-646. 2008
  • Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program..  50:581-587. 2008
  • Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?.  50:462-467. 2008
  • Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program..  50:37-45. 2008
  • Reply to Comment on "Use of Patient Registries and Administrative Datasets for the Study of Pediatric Cancer"..  63:368. 2016
  • A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. 2017